J. Wälscher (Essen, Germany), C. Vancheri (Catania (CT), Italy)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
P. Cameli (Siena (SI), Italy), L. Bergantini (Siena (SI), Italy), M. D'Alessandro (Siena (SI), Italy), R. Refini (Siena (SI), Italy), M. Pieroni (Siena (SI), Italy), V. Alonzi (Siena (SI), Italy), P. Sestini (Siena (SI), Italy), E. Bargagli (Siena (SI), Italy)
|   |
Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study
L. Richeldi (Rome, Italy), K. Anstrom (North Carolina, United States of America), J. Behr (Munich, Germany), T. Corte (New South Wales, Australia), V. Cottin (Lyon, France), G. Jenkins (Nottingham, United Kingdom), N. Kamath (Welwyn Garden City, United Kingdom), Y. Inoue (Osaka, Japan), L. Islam (Welwyn Garden City, United Kingdom), S. Nathan (Virginia, United States of America), G. Raghu (Washington, United States of America), J. Randhawa (Welwyn Garden City, United Kingdom), S. Walsh (London, United Kingdom), F. Martinez (New York, United States of America)
| |
Challenges in setting up Phase III idiopathic pulmonary fibrosis studies during the COVID-19 pandemic: Experience from the STARSCAPE program
L. Richeldi (Rome, Italy), V. Cottin (Lyon, France), L. Islam (Welwyn Garden City, United Kingdom), G. Jenkins (Nottingham, United Kingdom), N. Kamath (Welwyn Garden City, United Kingdom), Y. Inoue (Osaka, Japan), N. Parmar (Welwyn Garden City, United Kingdom), J. Randhawa (Welwyn Garden City, United Kingdom), G. Raghu (Washington, United States of America)
| |
Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study
L. Thong Wan Yin (Co. Cork, Ireland), B. Bowen (Co. Cork, Ireland), M. Henry (Co. Cork, Ireland)
| |
Safety and effectiveness of mycophenolate mofetil in interstitial lung diseases
T. Karampitsakos (Patras, Greece), V. Tzilas (Athens, Greece), O. Papaioannou (Patras, Greece), E. Koukaki (Athens, Greece), M. Katsaras (Patras, Greece), E. Bouros (Athens, Greece), P. Tsiri (Patras, Greece), G. Tsirikos (Patras, Greece), E. Zarkadi (Patras, Greece), N. Ntoulias (Patras, Greece), V. Sotiropoulou (Patras, Greece), P. Efthymiou (Patras, Greece), S. Chrysikos (Athens, Greece), E. Malakounidou (Patras, Greece), F. Sampsonas (Patras, Greece), C. Kalogeropoulou (Patras, Greece), D. Bouros (Athens, Greece), A. Tzouvelekis (Patras, Greece)
| |
Long-term tolerability of real-life use of antifibrotic agents (AFA) in Idiopathic Pulmonary Fibrosis (IPF)
D. Strens (Leuven, Belgium), B. Bondue (Brussels, Belgium), C. Dahlqvist (Yvoir, Belgium), H. Slabbynck (Antwerp, Belgium), J. Guiot (Liège, Belgium), G. Joos (Ghent, Belgium), N. Gusbin (Liège, Belgium), G. Wirtz (Luxembourg City, Luxembourg), A. Froidure (Brussels, Belgium), W. Wuyts (Leuven, Belgium)
| |
Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study
M. Kato (Tokyo, Japan), A. Miyamoto (Tokyo, Japan), S. Izumi (Tokyo, Japan), M. Inomata (Tokyo, Japan), K. Kamio (Tokyo, Japan), H. Sumikawa (Osaka, Japan), R. Egashira (Saga, Japan), H. Sugiura (Tokyo, Japan), J. Araya (Tokyo, Japan), M. Takeuchi (Tokyo, Japan), K. Takahashi (Tokyo, Japan), A. Azuma (Tokyo, Japan)
| |
Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study
J. Barnes (Cambridge, United Kingdom), E. Harris (Cambridge, United Kingdom), L. Matos (Cambridge, United Kingdom), K. Harding (Cambridge, United Kingdom), M. Thillai (Cambridge, United Kingdom)
| |
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
J. Huh (Seoul, Republic of Korea), J. Lee (Busan, Republic of Korea), J. Song (Seoul, Republic of Korea)
| |
Phase 1 demonstrates LYT-100 (deupirfenidone) is dose-proportional and well-tolerated when given twice-daily over multiple ascending doses (MAD) and shows a minor food effect (FE)
M. Chen (Boston, United States of America), C. Korth (Boston, United States of America), M. Harnett (Boston, United States of America), J. Lickliter (Melbourne, Australia), E. Elenko (Boston, United States of America)
| |
Post-hoc analysis of DWN12088: Comparative analysis between fasting period and adverse event incidences in Healthy subjects
M. Park (Seoul, Republic of Korea), J. Heo (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), J. Han (Seoul, Republic of Korea)
| |
Does the questionnaire “human activity profile” assess functional capacity in patients with idiopathic pulmonary fibrosis?
H. Pereira (Belo Horizonte, Brazil), E. Mancuzo (Belo Horizonte, Brazil), G. Ribeiro-Samora (Belo Horizonte, Brazil), D. Estrella (Belo Horizonte, Brazil), A. Pataro (Belo Horizonte, Brazil), F. Rita (Belo Horizonte, Brazil), F. Pereira (Belo Horizonte, Brazil), V. Parreira (Belo Horizonte, Brazil)
| |
A Pilot Study on using SuperDimension when performing cryobiopsies.
S. Kronborg-White (Aarhus, Denmark), E. Bendstrup (Aarhus, Denmark), L. Gori (Florence, Italy), V. Luzzi ( Florence, Italy), L. Madsen (Aarhus, Denmark), V. Poletti (Forli, Italy), T. Rasmussen (Aarhus, Denmark), M. Trigiani (Florence, Italy), S. Vezzosi (Florence, Italy), S. Tomassetti (Florence, Italy)
| |
Instant diagnosing interstitial lung disease using higher harmonic generation microscopy
L. Van Huizen (Amsterdam, Netherlands), K. Kalverda (Amsterdam, Netherlands), V. Poletti (Aarhus, Denmark), P. Bonta (Amsterdam, Netherlands), M. Groot (Amsterdam, Netherlands), J. Annema (Amsterdam, Netherlands)
| |
A prospective evaluation of lung ultrasonography in patients with fibrotic interstitial lung diseases.
E. Vasarmidi (Heraklion (Crete), Greece), G. Pitsidianakis (Heraklion (Crete), Greece), E. Vassalou (Heraklion (Crete), Greece), M. Klontzas (Heraklion (Crete), Greece), A. Karantanas (Heraklion (Crete), Greece), N. Tzanakis (Heraklion (Crete), Greece), K. Antoniou (Heraklion (Crete), Greece)
| |
Unsupervised analysis of electronic nose data identifies patient clusters in fibrosing interstitial lung disease
I. van der Sar (Rotterdam, Netherlands), C. Moor (Rotterdam, Netherlands), M. Luijendijk (Rotterdam, Netherlands), P. Brinkman (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
| |
Diagnostic yield of transbronchial lung cryobiopsy for diffuse parenchymal lung diseases diagnosis: 1.7 mm and 1.9 mm probe
F. Sultani (Forlì, Italy), C. Ravaglia (Forlì, Italy), S. Puglisi (Forlì, Italy), S. Piciucchi (Forlì, Italy), A. Dubini (Forlì, Italy), L. Donati (Forlì, Italy), V. Poletti (Forlì, Italy)
| |
Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries.
M. Vasakova (Praha 4, Czech Republic), M. Sterclova (Praha 4, Czech Republic), N. Mogulkoç (Izmir, Turkey), K. Lewandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hajkova (Bratislava, Slovakia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Studnicka (Salzburg, Austria), D. Jovanovic (Belgrade, Republic of Serbia), N. Stoeva (Sofia, Bulgaria), K. Kirchgässler (Basel, Switzerland), S. Littnerova (Brno, Czech Republic), O. Majek (Brno, Czech Republic), J. Gregor (Brno, Czech Republic)
| |
Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study
E. Lee (Seoul, Republic of Korea), T. Lee (Seoul, Republic of Korea), Y. Hong (Seoul, Republic of Korea), J. Ryoo (Seoul, Republic of Korea), J. Heo (Seoul, Republic of Korea), H. Kang (Seoul, Republic of Korea), S. Kwon (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea)
| |